https://www.lucamaini.com/working-papers daily 0.75 2026-04-27 https://www.lucamaini.com/working-papers/2025/10/31/insurance-design-and-the-passthrough-of-nominal-drug-prices monthly 0.5 2025-11-04 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/22feb480-eb10-4959-acee-45fe9e1c38bd/presentation_graphic_model.png Working Papers - Insurance Design and the Passthrough of Nominal Drug Prices - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/11e015b6-bc1c-4efc-a64a-a11fb5810b34/web_table1.png Working Papers - Insurance Design and the Passthrough of Nominal Drug Prices - Make it stand out Table 1. Effect of list price growth on OOP cost growth in commercial plans https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/253835cb-64a3-4560-95ee-38f6092a003d/web_table2.png Working Papers - Insurance Design and the Passthrough of Nominal Drug Prices - Make it stand out Table 2. Effect of list price growth on OOP cost growth in Medicare Part D plans https://www.lucamaini.com/working-papers/2023/8/3/stocking-under-the-influence-spillovers-from-commercial-drug-coverage-to-medicare-utilization monthly 0.5 2025-05-20 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/7be20404-4020-40ba-9505-3d6ff88a3507/flowchart.JPG Working Papers - Stocking Under the Influence: Spillovers from Commercial Drug Coverage to Medicare Utilization - Make it stand out Figure 1. Diagram for impact of facility formularies https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/89718791-ec9d-46f5-97ec-b0e7d8f32c67/table+for+website.png Working Papers - Stocking Under the Influence: Spillovers from Commercial Drug Coverage to Medicare Utilization - Make it stand out Table 1: Impact of Commercial Coverage on Part B Utilization https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/498ee46a-e3ee-4211-9a96-0d4984b5ef54/Figure+2.jpg Working Papers - Stocking Under the Influence: Spillovers from Commercial Drug Coverage to Medicare Utilization - Make it stand out Figure 2. Variation in prescribing that is explained by facility-level factors https://www.lucamaini.com/other-writing daily 0.75 2026-04-27 https://www.lucamaini.com/other-writing/2024/4/1/pharmaceuticals monthly 0.5 2024-11-12 https://www.lucamaini.com/other-writing/2024/4/1/pharmaceuticals-84z4a monthly 0.5 2026-02-19 https://www.lucamaini.com/other-writing/2020/12/30/where-is-the-good-stuff-drug-quality-measures-and-economic-research monthly 0.5 2025-05-17 https://www.lucamaini.com/health-policy-publications daily 0.75 2026-04-27 https://www.lucamaini.com/health-policy-publications/2026/3/12/trends-in-prescription-drug-coverage-restrictions-in-medicare-medicaid-and-commercial-insurance-plans-2011-2019 monthly 0.5 2026-03-12 https://www.lucamaini.com/health-policy-publications/2025/12/5/savings-from-biosimilars-and-medicare-formulary-access monthly 0.5 2025-12-05 https://www.lucamaini.com/health-policy-publications/2025/11/3/onq96ofj5aqfnf2qhuzllfdo7ri2rx monthly 0.5 2025-11-04 https://www.lucamaini.com/health-policy-publications/2024/10/7/medicare-part-d-savings-under-the-manufacturer-discount-program-vs-coverage-gap-discounts monthly 0.5 2025-09-10 https://www.lucamaini.com/health-policy-publications/2025/9/10/challenges-in-delivering-most-favored-nation-pricing-for-prescription-drugs-in-the-us monthly 0.5 2025-09-10 https://www.lucamaini.com/health-policy-publications/2024/10/7/medicare-part-d-protected-class-policy-is-associated-with-lower-drug-rebates monthly 0.5 2025-11-04 https://www.lucamaini.com/health-policy-publications/2024/5/6/benefit-design-and-biosimilar-coverage-in-medicare-part-d-evidence-and-implications-from-recent-reforms monthly 0.5 2024-11-12 https://www.lucamaini.com/health-policy-publications/2024/4/1/patient-out-of-pocket-costs-for-biologic-drugs-after-biosimilar-competition monthly 0.5 2025-05-17 https://www.lucamaini.com/health-policy-publications/2023/11/13/dymo4gf0pctexkgn6tbl2kc1dreahg monthly 0.5 2024-04-02 https://www.lucamaini.com/health-policy-publications/2020/12/31/price-increases-of-protected-class-drugs-in-medicare-part-d-relative-to-inflation-2012-2017-cdaaj monthly 0.5 2023-11-16 https://www.lucamaini.com/health-policy-publications/2020/12/31/price-increases-of-protected-class-drugs-in-medicare-part-d-relative-to-inflation-2012-2017 monthly 0.5 2023-11-16 https://www.lucamaini.com/health-policy-publications/2020/12/31/has-the-era-of-slow-growth-for-prescription-drug-spending-ended monthly 0.5 2025-05-17 https://www.lucamaini.com/economics-publications daily 0.75 2026-04-27 https://www.lucamaini.com/economics-publications/2020/12/30/biosimilar-entry-and-the-pricing-of-biologic-drugs monthly 0.5 2026-04-04 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609366855547-TSS1WV7GJZE77S8FTKGD/biologic_biosimilar_com.jpg Publications in Economics - Biosimilar Entry and the Pricing of Biologic Drugs https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/fae36555-ab10-4004-bd28-5432569e0726/price_graph_web.png Publications in Economics - Biosimilar Entry and the Pricing of Biologic Drugs List and net price trends of reference biologics around biosimilar entry https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609368228109-KJRBGPY369EMW3HLDAWI/entrant+best+response+price+simple.png Publications in Economics - Biosimilar Entry and the Pricing of Biologic Drugs Optimal pricing rule of the biologic incumbent as a function of the difference in vertical quality with the biosimilar entrant. https://www.lucamaini.com/economics-publications/2023/7/26/mergers-that-matter-the-impact-of-mampa-activity-in-prescription-drug-markets monthly 0.5 2026-01-21 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/b381205c-d2b2-4262-8a2b-2d7a879568be/Figure2b_pres.png Publications in Economics - Mergers that Matter: The Impact of M&A Activity in Prescription Drug Markets - Make it stand out Figure 1. Overview of M&A activity in the US pharmaceutical market https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/63d822ec-7de2-42e8-bf43-39548353fcaa/Figure4b_pres.png Publications in Economics - Mergers that Matter: The Impact of M&A Activity in Prescription Drug Markets - Make it stand out Figure 2. Effect of horizontal acquisitions on estimated net prices https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/78ba0455-bb23-4e9c-854d-0d5fbe89410d/Figure8a_pres.png Publications in Economics - Mergers that Matter: The Impact of M&A Activity in Prescription Drug Markets - Make it stand out Figure 3. Effect of cross-market acquisitions on estimated net price https://www.lucamaini.com/economics-publications/2021/9/9/demand-inertia-and-the-hidden-impact-of-pharmacy-benefit-managers monthly 0.5 2025-03-11 https://www.lucamaini.com/economics-publications/2020/12/30/profiting-from-most-favored-customer-procurement-rules-evidence-from-medicaid monthly 0.5 2024-03-20 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609520795352-HDRSUF6F8H1M60LMGZ7N/medicaid_fig1.png Publications in Economics - Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609363557966-U8W3EG2JE6GWEZ5HV74X/bargaining+intuition_v2.png Publications in Economics - Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609365545949-3NJ91MGTLE46N3PFCNY5/image-asset.png Publications in Economics - Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid Diff-in-diff estimates of the change in non-Medicaid discount rates for drugs with high Medicaid Market Share after the ACA rule change. https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609365629566-D3NBYQQMKDTE9HDIME5C/image-asset.png Publications in Economics - Profiting from Most-Favored Customer Procurement Rules: Evidence from Medicaid Diff-in-diff estimates of the change in non-Medicaid revenue for drugs with high Medicaid Market Share after the ACA rule change. https://www.lucamaini.com/economics-publications/2020/12/30/reference-pricing-as-a-deterrent-to-entry-evidence-from-the-european-pharmaceutical-market monthly 0.5 2026-01-21 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609348558561-93LXBXIVFW5EPBYRGECD/image-asset.png Publications in Economics - Reference Pricing as a Deterrent to Entry: Evidence From the European Pharmaceutical Market https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609346703541-10127OMBXLKIQJU82SQJ/image-asset.png Publications in Economics - Reference Pricing as a Deterrent to Entry: Evidence From the European Pharmaceutical Market Fraction of new drugs available in select European countries 6 years after approval. Source: IMS Health and EMA https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609358680311-7D9SIOU9TAQSYDPMU19D/ERP_fig2.png Publications in Economics - Reference Pricing as a Deterrent to Entry: Evidence From the European Pharmaceutical Market https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1609359385145-P4SCEEWD1QPP31DTPT7W/delay_loss_map.png Publications in Economics - Reference Pricing as a Deterrent to Entry: Evidence From the European Pharmaceutical Market Marginal impact of reference pricing on delays by country https://www.lucamaini.com/home daily 1.0 2026-02-19 https://images.squarespace-cdn.com/content/v1/5b3660f9b98a78542ce0faa9/1530382560087-YQLFHD59TMR0BO4KWK5Z/home_photo home https://www.lucamaini.com/teaching daily 0.75 2025-07-22 https://www.lucamaini.com/research daily 0.75 2025-11-04 https://www.lucamaini.com/data daily 0.75 2024-08-13